Viatris (VTRS) Total Current Liabilities (2019 - 2026)
Viatris (VTRS) posted quarterly Total Current Liabilities of $6.8 billion for Q1 2026, up 19.06% year-over-year from $5.7 billion in Q1 2025, and down 4.0% quarter-over-quarter from $7.1 billion in Q4 2025.
Viatris (VTRS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $6.8 billion for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 19.06% year-over-year to $6.8 billion; the TTM figure through Mar 2026 stood at $6.8 billion (up 19.06% YoY), while the FY2025 annual figure was $7.1 billion, up 22.75% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $6.8 billion, down from $7.1 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $9.6 billion in Q1 2022, with the low at $5.7 billion in Q1 2025.
- The 5-year median for Total Current Liabilities is $7.1 billion (2025), against an average of $7.1 billion.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slumped 36.66% in 2023, then increased 27.04% in 2024.
- Viatris' Total Current Liabilities stood at $6.7 billion in 2022, then increased by 15.29% to $7.8 billion in 2023, then fell by 25.69% to $5.8 billion in 2024, then climbed by 22.75% to $7.1 billion in 2025, then declined by 4.0% to $6.8 billion in 2026.
- Business Quant data shows VTRS's Total Current Liabilities at $6.8 billion in Q1 2026, $7.1 billion in Q4 2025, and $7.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 1.79 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 662.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.35 Bn |
| Mar 31, 2026 | 6.81 Bn |
| Dec 31, 2025 | 7.09 Bn |
| Sep 30, 2025 | 7.36 Bn |
| Jun 30, 2025 | 7.13 Bn |
| Mar 31, 2025 | 5.72 Bn |
| Dec 31, 2024 | 5.78 Bn |
| Sep 30, 2024 | 7.51 Bn |
| Jun 30, 2024 | 7.71 Bn |
| Mar 31, 2024 | 7.76 Bn |
| Dec 31, 2023 | 7.78 Bn |
| Sep 30, 2023 | 6.83 Bn |
| Jun 30, 2023 | 6.52 Bn |
| Mar 31, 2023 | 6.11 Bn |
| Dec 31, 2022 | 6.75 Bn |
| Sep 30, 2022 | 6.52 Bn |
| Jun 30, 2022 | 7.68 Bn |
| Mar 31, 2022 | 9.64 Bn |
| Dec 31, 2021 | 9.88 Bn |
| Sep 30, 2021 | 10.10 Bn |